About diabetes

Type 1 diabetes is an autoimmune disease in which insulin-producing beta cells in the pancreas are mistakenly destroyed by the body’s immune system. It impairs patient’s metabolism, affecting how they process and store glucose from blood. It occurs in children and adults. Its causes are not fully known, and there is currently no cure.

People with type 1 diabetes are dependent on injected or pumped insulin for the rest of their life to regulate blood glucose levels (glycemia). While current therapeutic approaches for type 1 diabetes save lives, less than 1 out of 5 patients achieves a controlled glycemia with exogenous insulin; in addition, cardiovascular complications often impact the overall life expectancy of diabetic patients and alter quality of life. Furthermore, insulin administration can be disruptive to daily activities as it needs to be injected 2-4 times a day and to monitor glucose levels requires glycemia monitoring by finger prick before each meal and bed. This translates in continuously planning several aspects of their daily life (e.g., fasting time, meal size, sport intensity), limiting their quality of life.

Currently, due to complications derived from diabetes, life expectancy for T1D patients is about 10-15 years shorter than the general population. Diabetes is the leading cause of preventable blindness, end-stage renal disease and non-traumatic amputation. It doubles the risk of cardiac death and stroke.

Today, it is estimated that more than 8.7 million people worldwide live with Type 1 diabetes, a number expected to grow to more than 17 million by 2040

Sources: JDRF, T1Dindex.org, Lancet Diabetes Endocrinol.

Type 1 Diabetes

8.7 million people living with T1D worldwide

+100% by 2040

1.8 million Americans receive insulin 

achieve a controlled glycemia with exogenous insulin

Consequences of micro & macrovascular complications


risk of cancer death and stroke


cause of preventable blindness


cause of end-stage renal disease¹ 


cause of non-traumatic amputation

Sources : International diabetes association

(1) will affect 30% of T1D patients

Additional opportunities in T2D

  • 480 million people worldwide
  • Metabolic disease
  • 27% of patients receive insulin (6 million Americans)
  • Fierce competitive landscape (SGLT2, GLP1, DPP-4)

Quelques chiffres


million adults (20-79 years old) have diabetes globaly (1 in 11 person) (1)


Adults living with diabetes has more than tripled over the past 20 years (1)


million people live with Type 1 Diabetes globally (2)


of T1D patients in the US experience one or more severe hypoglycemic events annually (3)


USD worldwide annual T1D cost burden (2)


  1.  IDF Diabetes Atlas Ninth edition 2019
  2. https://t1dfund.org/modeling-the-total-economic-value-of-novel-type-1-diabetes-therapeutic-conepts/
  3. McCrimmon, R.J. and R.S. Sherwin, hypoglycemia in type 1 diabetes. Diabetes, 2010. 59(10): p. 2333-2339.; Frier, B.M., The incidence and impact of hypoglycemia in type 1 and type 2 diabetes. Internation Diabetes MOnitor, 2009. 21(6): P. 210-216